{"schema_version":"secwatch.filing_event.v1","accession":"0001757073-22-000064","form_type":"8-K","ticker":"NVST","cik":"0001757073","company_name":"Envista Holdings Corp","filed_at":"2022-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.187248+00:00","generated_at":"2026-06-25T12:20:48.720677+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Envista to acquire Osteogenics Biomedical for ~$30M annual sales; closes Q3","bullets":["Definitive agreement to acquire Osteogenics Biomedical, Allotech, OBI Biologics (Cytoplast brand).","Osteogenics has ~$30M annual sales; leader in regenerative solutions for dental bone grafting.","Transaction subject to customary regulatory approvals; expected close in Q3 2022.","No financing condition or shareholder vote required; funded from existing resources."],"urls":{"canonical":"https://secwatch.observer/filing/0001757073-22-000064","json":"https://secwatch.observer/filing/0001757073-22-000064.json","markdown":"https://secwatch.observer/filing/0001757073-22-000064.md","text":"https://secwatch.observer/filing/0001757073-22-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757073/000175707322000064/0001757073-22-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757073/000175707322000064/nvst-20220517.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T12:20:48.720677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}